The $20M dilutive placement at $0.454/share creates massive overhang; watch for continued selling pressure as the market absorbs the new shares. Monitor Q3 2026 for tissue-based test volume acceleration and progress toward the $110-115M revenue guidance, which is critical for any recovery narrative.
Price Chart
Executive Summary
MDxHealth reported Q2 2026 revenue of $27.2M (+16% YoY), but net loss widened 36% to $9.5M and operating loss surged 236% to $5.1M due to ExoDx acquisition costs. The company completed a $20M dilutive registered direct placement on August 11, 2026, issuing 44M shares at $0.454, and wound down its Resolve business via an Assignment for the Benefit of Creditors. While revenue growth is positive, the massive dilution, deepening losses, and negative adjusted EBITDA (-$2.3M) outweigh the top-line beat, making this a bearish event for existing shareholders.
Key Facts
- Q2 2026 revenue from continuing operations was $27.2M, up 16% YoY from $23.4M.
- Net loss from continuing operations widened 36% to $9.5M from $6.96M YoY.
- Operating loss surged 236% to $5.1M from $1.5M YoY, driven by ExoDx acquisition expenses.
- Adjusted EBITDA was negative $2.3M, compared to positive $1.1M in Q2 2025.
- On August 11, 2026, the company raised $20M via a registered direct placement of 44,052,862 shares at $0.454 per share, causing ~84% dilution vs. pre-offering share count.
- Cash and cash equivalents were $19.2M at June 30, 2026; pro-forma including the placement is $39.2M.
- The Resolve UTI business was discontinued; subsidiary Delta Labs executed an Assignment for the Benefit of Creditors on August 3, 2026, addressing a $10.4M recoupment claim.
- Tissue-based test volume was 12,525 (down 1% YoY but up 13% sequentially); liquid-based Exo mdx volume was 13,578.
Financial Impact
Revenue grew 16% to $27.2M, but net loss increased 36% to $9.5M. A $20M dilutive equity offering added ~44M shares, increasing share count by roughly 84% from pre-offering levels.
Risk Factors
- Massive shareholder dilution (~84% from the August 11 placement) will pressure EPS and stock price.
- Operating losses are widening significantly due to ExoDx integration costs; path to positive adjusted EBITDA remains uncertain.
- The Resolve wind-down via ABC introduces legal and creditor risk, though it is ring-fenced to the Delta Lab subsidiary.
- High debt load ($96.4M in loans and borrowings) against negative equity (-$30.4M) raises solvency concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-089069 |
| Document: ea0301975-6k_mdxhealth.htm | 0001213900-26-089069 |
| Document: 0001213900-26-089069-index-headers.html | 0001213900-26-089069 |
| Document: 0001213900-26-089069-index.html | 0001213900-26-089069 |
| Document: 0001213900-26-089069.txt | 0001213900-26-089069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1874 (+9.47%) |
Oct 15, 2026 11d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1874 (+9.29%) |
Oct 15, 2026 11d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1874 (+9.29%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1874 (+70.25%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1874 (+74.96%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1874 (+76.81%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1874 (−76.81%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1874 (+55.17%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1874 (+60.67%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1874 (−90.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers